Do the Statistics: The Prevalence Risk, Prevalence Rate, Incidence Rate in connection with the Vaccination of Dengvaxia.
DENGVAXIA: As medicine to cure dengue infections
Nitong mga nakaraang araw ay nagulat ang lahat sa paglalabas ng resulta ng kanilang isinagawang pag-aaral. Ito ay sa kadahilanang may masamng epekto ang gamot sa mga pasyenteng hindi pa nagkakaroon ng history ng dengue infections bago ang vaccinations.
Sa madaling salita, kapag ang isang bata ay hindi pa nagkakaroon ng history ng dengue at siya ay nabakunahan ng Dengvaxia, siya ay may mataas na risk na magkaroon ng mas marami o mas malalang komplikasyon or infections in the future.
Sa interview kay Dr. Francisco Duque noong Disyembre 1, kanyang sinabi na mayroong 733, 717 records of children ang nabakunahan ng Dengvaxia na wala pang any history ng Dengue, therefore these number of people are at risk of having more complications in the future.
Sa Website naman ng DOH, tinatayang mayroong bilang na 66, 299 suspected Dengue patients ang kanilang naitala mula January 1, 2016 - July 2016. In the same report, nakasaad na 480 lamang ang confirmed patients na may dengue.
Kung ganun, malaking bahagi ng mga kabataang nasa edad na 9 pataas ay nanganganib na magkaroon ng marami or malalang komplikasyon sa mga susunod na mga buwan or taon bilang epekto ng Dengvaxia.
Historical Implementations
Based on records, the Philippines was the 1st country in Asia to approve the vaccine for individuals aged 9-year-old and 45-year-old in December 2015.
The Government during Aquino's administrations has since procured P3 - billion worth of Dengvaxia intended for one (1) million public school children in areas reported to have the highest incidence of Dengue in 2015, the vaccine has to be administered in three phases at 6-months intervals beginning April 2016.
A total of 491, 990 were vaccinated in the first phase under then Health Secretary Janette Garin. Of that number, 415,681 turned up for the second phase, which by then was implemented by Garin's successor, Secretary Paulyn Ubial. (Note: may issue about Paulyn Ubial when she was not appointed di ba?)
TYPES PREVALENCE
1. Point prevalence measures the Frequency of existing disease in a defined population at a single point in time.
2. Period prevalence measures the Frequency of the total number of cases over a particular period of time.
INCIDENCE
Total number of new cases over a particular time period
DATA:
733,717 = are the numbers of children vaccinated with Dengvaxia who has no history of dengue in the past ages 9 years old and above. (Ito yung bilang ng mga batang nabakunahan ng Dengvaxia na hindi pa nagkakaroon ng Dengue Infections in the Past).
66, 299 = are the numbers of Suspected Dengue patients from January 1, 2016 - July 2016)
480 = are the numbers of patients with confirmed cases of dengue infections.
Sources of Data:
1. DOH
2. Live Interview
Nitong mga nakaraang araw ay nagulat ang lahat sa paglalabas ng resulta ng kanilang isinagawang pag-aaral. Ito ay sa kadahilanang may masamng epekto ang gamot sa mga pasyenteng hindi pa nagkakaroon ng history ng dengue infections bago ang vaccinations.
Sa madaling salita, kapag ang isang bata ay hindi pa nagkakaroon ng history ng dengue at siya ay nabakunahan ng Dengvaxia, siya ay may mataas na risk na magkaroon ng mas marami o mas malalang komplikasyon or infections in the future.
Sa interview kay Dr. Francisco Duque noong Disyembre 1, kanyang sinabi na mayroong 733, 717 records of children ang nabakunahan ng Dengvaxia na wala pang any history ng Dengue, therefore these number of people are at risk of having more complications in the future.
Sa Website naman ng DOH, tinatayang mayroong bilang na 66, 299 suspected Dengue patients ang kanilang naitala mula January 1, 2016 - July 2016. In the same report, nakasaad na 480 lamang ang confirmed patients na may dengue.
Kung ganun, malaking bahagi ng mga kabataang nasa edad na 9 pataas ay nanganganib na magkaroon ng marami or malalang komplikasyon sa mga susunod na mga buwan or taon bilang epekto ng Dengvaxia.
Historical Implementations
Based on records, the Philippines was the 1st country in Asia to approve the vaccine for individuals aged 9-year-old and 45-year-old in December 2015.
The Government during Aquino's administrations has since procured P3 - billion worth of Dengvaxia intended for one (1) million public school children in areas reported to have the highest incidence of Dengue in 2015, the vaccine has to be administered in three phases at 6-months intervals beginning April 2016.
A total of 491, 990 were vaccinated in the first phase under then Health Secretary Janette Garin. Of that number, 415,681 turned up for the second phase, which by then was implemented by Garin's successor, Secretary Paulyn Ubial. (Note: may issue about Paulyn Ubial when she was not appointed di ba?)
TYPES PREVALENCE
1. Point prevalence measures the Frequency of existing disease in a defined population at a single point in time.
2. Period prevalence measures the Frequency of the total number of cases over a particular period of time.
INCIDENCE
Total number of new cases over a particular time period
DATA:
733,717 = are the numbers of children vaccinated with Dengvaxia who has no history of dengue in the past ages 9 years old and above. (Ito yung bilang ng mga batang nabakunahan ng Dengvaxia na hindi pa nagkakaroon ng Dengue Infections in the Past).
66, 299 = are the numbers of Suspected Dengue patients from January 1, 2016 - July 2016)
480 = are the numbers of patients with confirmed cases of dengue infections.
Sources of Data:
1. DOH
2. Live Interview
Comments
Post a Comment